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Epstein-Barr virus (EBV) is associated with the development of several types of human cancers and is an
important cause of lymphomas in immunocompromised hosts. Expression of the EBV BZLF1 immediate-early
gene product (Z) triggers disruption of latency in EBV-infected cells. Z is a member of the b-Zip family of
proteins and binds to AP-1-like sites in early viral promoters. Here we show that a viral RNA related to Z, in
which there is replacement of the transactivation domain of Z by fusion through alternate splicing with a
portion of another EBV transactivator, BRLF1 (R), can repress Z function. This differentially spliced mRNA
is predicted to express a novel chimeric protein which we call RAZ for R and Z. RAZ retains the dimerization
and DNA-binding domains of Z but loses its transactivation domain. We show that in vitro the RAZ protein
acts transdominantly to repress transactivation of early promoters by Z. Repression is produced by
dimerization of RAZ with Z resulting in RAZ:Z heterodimers that can no longer bind to Z-binding sites despite
retention of the DNA-binding domains in both proteins. Deletion of the R domain of RAZ restores the ability
of the truncated RAZ homodimers and RAZ:Z heterodimers to bind to DNA. A biologic effect ofRAZ was shown
by cotransfection of latently infected Raji cells with Z and RAZ expression clones; RAZ diminished viral
reactivation induced by Z, as indicated by amount of early replicative antigens (EA-D) detected. The RAZ
protein presents a model for transcriptional control unique among the herpesviruses and distinct from
analogous viral and cellular repressors. RAZ, by limiting the availability of Z protein, is likely to modulate EBV
reactivation.
Epstein-Barr virus (EBV) is an oncogenic human herpesvi-
rus that infects two cell types, epithelial cells and lymphocytes.
The virus immortalizes B lymphocytes, producing in these
proliferating cells a latent infection in which only a subset of
the approximately 100 viral genes is expressed (for a review,
see reference 31). In such latently infected cells, viral replica-
tion and cytolysis are prevented. However, although there is
considerable information on the mechanism by which viral
reactivation is triggered, how reactivation is suppressed is
poorly understood and equally important.
Viral reactivation in vitro is produced by treatment of
latently infected cell lines with agents such as phorbol esters
(12), sodium butyrate (40), or anti-immunoglobulin (11, 55),
all of which have in common the ability to induce the expres-
sion of the key immediate-early gene, BZLFI, used in the
switch from latency to cytolytic replication (9). The product of
BZLF1, Z (also referred to as ZEBRA, Zta, and EBI), when
overexpressed by transfection into latently infected cells is
sufficient to trigger viral reactivation (7, 9, 51). In cotransfec-
tion experiments, Z is able to transactivate several early
promoters in EBV-infected lymphoblastoid cells and in EBV-
negative HeLa cells (6, 10, 26, 28, 38, 51) as well as to
autoregulate its own promoter (17). Deletional and mutational
analysis of these promoters has revealed a consensus Z-
responsive element (ZRE) (T[G/T][A/T]G[T/C][G/C/A]A)
(32, 36, 47) which conveys Z inducibility when placed upstream
of a heterologous promoter.
Z is a member of the b-Zip family of transcription factors
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and has significant amino acid homology within the basic
DNA-binding and dimerization domains of c-Fos (15) and
C/EBP (32). Z functions as a homodimer and binds to authen-
tic AP-l sites (T[G/T][A/C][G/C]TCA) (15), as well as to
consensus C/EBP binding sites (T[T/G]NNG[C/T]AA[T/G])
(32) and somewhat degenerate AP-1 sites (5, 17, 36, 47).
Another EBV immediate-early protein, the BRLF1 gene
product (R) (also known as Rta), is also a sequence-specific
DNA-binding protein and transcriptional transactivator (24,
25, 41). In addition, in certain cell types, R can act synergisti-
cally with Z to produce transcriptional transactivation (10, 26).
However, the possibility that the Z transactivation effect might
also be negatively regulated by viral gene products has until
now not been studied.
The immediate-early region of the EBV genome generates
Z and R viral transactivators by the use of two promoters and
differential splicing as shown in Fig. IA (41). Both the pZ and
pR promoters play a role in disruption of latency (18). pZ gives
rise to a 1-kb transcript encoding the Z transactivator. Z is
composed of three exons generating a 245-amino-acid (aa)
protein that migrates at 38 kDa on sodium dodecyl sulfate
(SDS) gels. Z has well-characterized transactivation, basic-
DNA-binding, and dimerization domains (16, 32, 36) (see Fig.
IB) and has recently been shown to interact with TFIID (37).
pR is responsible for three transcripts of 4.0, 3.3, and 0.8 kb
(41). The 4.0- and 3.3-kb transcripts are bicistronic and encode
both the BZLF1 and the BRLF1 transactivators.
In this paper, we report the characterization of the alter-
nately spliced 0.8-kb transcript generated from pR first de-
tected by Manet et al. (41) but never characterized. This
transcript is predicted to encode a chimeric protein consisting
of the dimerization and DNA-binding domains of Z and an
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amino-terminal domain derived from R. In vitro, this protein,
designated RAZ (BRLF1 and BZLF1), can transdominantly
inhibit Z transactivation by forming RAZ:Z heterodimers that
are unable to bind to ZREs.
Alternate splicing is an efficient mechanism for the genera-
tion of a transdominant repressor from the same gene that
encodes a transcriptional transactivator (for a review, see
reference 20). Structurally, many transdominant repressors
contain deletions or domain substitutions within the transacti-
vation domain resulting in a protein that competes with the
activator for binding to the same site and thus blocks activation
of transcription (8, 14, 19, 34, 45, 46, 56). RAZ represents a
new type of an alternately spliced transdominant repressor
whose action is to inhibit DNA binding through heterodimer-
ization with the target transactivator protein. Biologically,
RAZ may play an important role in curtailing viral reactivation
in EBV-transformed cells.
MATERIALS AND METHODS
Cell lines. The EBV-positive Akata (11, 55) and Raji (48)
cell lines were maintained in RPMI medium supplemented
with 10% fetal calf serum. The human cervical epithelial cell
line HeLa was maintained as monolayers in Dulbecco's mod-
ified Eagle medium H supplemented with 10% fetal calf
serum. Cells were maintained at 37°C in a 5% CO2 environ-
ment. Virus replication was induced in Akata cells by treat-
ment with 100 jig of anti-human immunoglobulin G (IgG) per
ml of medium (Sigma). Virus production was monitored by
indirect immunofluorescence for early antigen and viral capsid
antigen by using high-titer EBV-positive sera from patients
with nasopharyngeal carcinoma and fluorescein isothiocya-
nate-conjugated goat anti-human antibody.
Plasmids and DNA transfections. The plasmid pEA-BS-
CAT was made by inserting the XbaI-BamHI fragment of
pEA-CAT (which contains the complete BMRF1 promoter
sequences [positions 79,537 to 79,898], the chloramphenicol
acetyltransferase [CAT] gene and the simian virus 40 polyad-
enylation site) into the XbaI-BamHI site of the M13 Bluescript
SK+ plasmid (Stratagene) (26). pPolCAT contains the DNA-
polymerase promoter in a 1.29-kb BalI fragment (EBV nucle-
otides 156,859 to 158,149) cloned into the HincIl site upstream
of the CAT gene of pBS.CAT (21). pBHRF1-CAT (a gift from
Q. Zhang) contains the EBV sequences from nucleotides
52,799 to 53,819 cloned into the HinclI site of pBS.CAT. The
pEBV-ZIE plasmid contains the BamHI Z gene fragment
(EBV nucleotides 101,741 to 103,947) in the pGEM2-based
vector pHD1O13 (13), so that the BZLF1 gene is under the
control of the human cytomegalovirus immediate-early pro-
moter. The pEBV-R/Z plasmid contains both the BRLF1 and
BZLF1 transactivators under the control of the cytomegalo-
virus immediate-early promoter. This plasmid has the 4,061-bp
BgllI-BglII fragment (EBV nucleotides 101,351 to 105,412)
inserted into the BamHI site of the vector pHD1O13. Plasmid
DNA was purified either by two sequential cesium-chloride
gradients or by the Quiagen system. DNA was transfected into
both lymphoid and epithelial cell lines by electroporation (26).
For each condition, 107 cells were shocked at 1,500 V with the
Zapper electroporation unit (Medical Electronics Shop, Uni-
versity of Wisconsin). Epithelial cells were harvested and
resuspended into RPMI medium for electroporation.
CAT assays. At 48 h after transfection, cell extracts were
prepared from electroporated cells and incubated at 37°C with
['4C]chloramphenicol and acetyl coenzyme A (23). The per-
cent acetylation of chloramphenicol was quantitated by thin-
layer chromatography followed by scintillation counting or
scanning of the chromatography plates by scanner (AMBIS,
Inc.) for 10 h. If results were not in the linear range, CAT
assays were repeated with less extract.
cDNA synthesis and PCR amplification. Mock- or anti-IgG-
induced Akata cells were harvested, pelleted, and washed in
phosphate-buffered saline (PBS); total cellular RNA was ex-
tracted with guanidinium isothiocyanate (53). For RNA-based
PCR analysis, 1 jig of total cellular RNA was incubated at 42°C
for l h in a total volume of 20 [l containing 500 ng of oligo(dT)
primer, 1 mM each deoxynucleoside triphosphate, 1 mM
dithiothreitol (DTT), 50 mM Tris-HCl (pH 8.3), 75 mM KCl,
3 mM MgCl2, 10 U of RNase inhibitor, and 2 IlI of Superscript
RNase H- RT (Life Technologies; 200 U/RlI). After first-
strand cDNA synthesis, the reaction mixture was diluted to 50
[LI with Tris-EDTA (TE). A I-RI aliquot of each diluted
reaction mixture was used in a 50-pl PCR mixture containing
1 x Promega Taq DNA polymerase buffer, 1 mM each primer,
250 mM (each) deoxynucleotide triphosphates and 2.5 U of
Taq DNA polymerase (Promega). Thermal cycling conditions
for RAZ and R/Z cDNAs were 2 initial cycles at 94°C for
2 min, 55°C for 2 min, and 72°C for 3 min, followed by 23 cycles
at 94°C for 1 min, 55°C for 1 min, and 72°C for I min.
Amplification for actin cDNA was essentially the same except
that the total number of cycles was varied at 15, 20, and 25
cycles to achieve a subplateau range of amplification. Primers
specific for R/Z bicistronic cDNA were A (CAGAATCGC
ATICCTCCAGCGA) and B (GAATGTCTGCTGCATGCC
ATGC); for RAZ-specific cDNA amplification, primers were
A and C (ATGACGAGGGATCCTCTAGAGCCATGAGG
CCTAAAAAGGATGG); and for actin cDNA amplification,
primers were Act-I (CCTTCCTGGGCATGGAGTC) and
Act-2 (GGAGCAATGATCTTGATCTFC). PCR products
were resolved on a 1% agarose gel, blotted onto nitrocellulose
filters, fixed by heat, and prehybridized for 1 h at 37°C in
prehybridization solution containing 6 x SSC (1 x SSC is 0.15
M NaCl plus 0.015 M sodium citrate), 5 x Denhardt's solution,
0.15% sodium PPi, 100 jig of salmon sperm DNA per ml, and
0.1% SDS. Hybridization was performed in the same solution
at 37°C with a 32P-end-labelled R/Z- and RAZ-specific oligo-
nucleotide probe, AGGTGCTTCTCCCCCGGCTTGGTTAG
TCTGTTGATTCTG, or actin-specific probe, CTGTGTTG
GCGTACAGGTCTTrTlGCGGATGT. Filters were washed at
50°C in 0.1 x SSC-0.1% SDS, and products were visualized by
autoradiography.
DNA mobility shift assays. For mobility shift assays per-
formed with programmed rabbit reticulocyte lysates, 3 IlI of
each translation product was mixed with 20,000 cpm of a
32P-labelled ZRE-containing EBV-DNA probe from the
BamHI A fragment (coordinates 156,860 to 157,006) (21) in 25
Rl of 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic acid) (pH 7.9)-10% (vol/vol) glycerol-60 mM
KCl-0.1 mM EDTA-0.25 mM DTT-2 jig of poly(dI dC).
Binding reactions were carried out for 20 min at 27°C and
loaded onto 4% nondenaturing acrylamide gels, which were
electrophoresed in 0.25 x Tris-borate-EDTA, dried, and visu-
alized by autoradiography.
RAZ cDNA cloning. RAZ-specific cDNAs were PCR ampli-
fied from a XgtlO cDNA library prepared from EBV-positive
B95-8 cells (22). Briefly, total lambda DNA was prepared from
107 library PFU (53) and resuspended in 100 RIl of TE. One
microliter of this stock was PCR amplified with a RAZ 3'
primer (ATCACGAGGGATCCAAACCACACGATGCTAA
GAGAGCCGACAGGAAGA) and primer C. RAZ cDNAs
were cloned into phagemid pBS+ (Stratagene), sequenced,
and compared with the published B95-8 sequence (1) for any
mutations.
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Construction of RAZ mutants and in vitro expression.
RAZADIM was constructed by PCR mutagenesis. Briefly, 2 pug
of pBScRAZ single-stranded phagemid DNA was annealed in
1 x annealing buffer (40 mM Tris-HCl [pH 7.5], 20 mM
MgCl2, 50 mM NaCl) with 4 pmol of kinased primer (CC
GGGGGATAATGGAGTGCTGCAGCAGTTG) that was
discontinuous with RAZ cDNA sequence and annealed to 15
bases on either side of the dimerization domain (aa 207 to
235). Second-strand DNA was synthesized with the addition of
5 U of T7 DNA polymerase (Stratagene), 1 x reaction buffer
(10 mM Tris-HCl [pH 7.5], 2 mM DTT, 0.5 mM deoxynucleo-
side triphosphates, 1 mM ATP), and 3 U of T4 DNA ligase
(Promega), and synthesis was allowed to proceed at 27°C for 1
h. Subsequently, the reaction mixture was diluted to 100 iLl
with TE, and PCR amplification was performed with the RAZ
3' primer and primer C. For generation of RAZAR, aa 87 to
252 were PCR amplified from pBScRAZ with primers
RAZAR' (ATCACGAGGGATCCTCTAGAGCCACCATG
CCTGCTCCTGAGAATGCI7rATC) and RAZ 3'. Both
PCR-generated mutants were cloned into pBS+ and fully
sequenced. For in vitro transcription and translation,
pBS+cRAZ, RAZAR, and RAZADIM plasmid DNAs were
linearized with EcoRI (Promega) transcribed with T7 RNA
polymerase, and transcripts were used to program rabbit
reticulocyte lysates (Promega). pSP64Z was linearized with
EcoRI, andSP6 RNA polymerase was used to generate Z
transcripts. For cotranslations, transcripts were mixed and
added to reticulocyte lysates with or without [35]methionine.
35S-labelled proteins were resolved by SDS-10% polyacrylam-
ide gel electrophoresis (PAGE) and quantitated by densitom-
etry.
GST-RAZ and GST-Z bacterial expression and dimeriza-
tion assays. cRAZ was recovered from the pBScRAZ vector
with BamHI and cloned into the same site of pGEX2T
(Pharmacia) to create pGEX2T-cRAZ. The Z cDNA was
recovered from pSP64Z with BamHI and EcoRI, blunt ended
with Klenow enzyme, and cloned into the SmaI site of
pGEX3X to create pGST-Z. Escherichiacoli BL21DE3-pLysS
(Novagen) was transformed with pGEX2T-cRAZ and
pGST-Z, and fusion-protein expression was induced from
mid-log-phase cultures with 0.1 mM IPTG (isopropyl-P-D-
thiogalactopyranoside) for 1 h at30°C. To prepare bacterial
lysates, 10 ml of induced cultures was pelleted and resus-
pended in 1 ml of PBS, sonicated, and cleared of bacterial
debris by centrifugation at 12,000 x g. A total of 100ul of
glutathione-Sepharose 4B beads (Pharmacia) was added to the
cleared lysate to purify fusion proteins, and this addition was
followed by three centrifugations and washing in 1-ml aliquots
of PBS and a final resuspension in 100,ul of ELB+ (250 mM
NaCl, 0.1% Nonidet P-40, 50 mM HEPES [pH 7.0], 5 mM
EDTA [pH 8.0], 0.5 mM DTT, and 1 mM phenylmethylsul-
fonyl fluoride). For dimerization experiments,20-pul aliquots of
fusion protein bound to beads were incubated with 5 pA of
programmed reticulocyte lysates in 1 ml of ELB+ for 2 h at
4°C. Bead complexes were washed five times in 1 ml of ELB+
buffer, pelleted, and boiled in Laemmli sample buffer. Bound
proteins were resolved on SDS-10% polyacrylamide gels and
visualized by fluorography and autoradiography.
Immunoblotting. Raji cells were transfected as described
above, and cells were harvested 24 h after transfection, washed
twice with PBS, and resuspended in 200plI ofELB+ buffer.
Cells were then lysed by sonication for 10 s, and the lysate was
cleared by centrifugation for 10min at4°C. Protein concen-
tration of the samples was determined by the Bradford
method. Samples were resuspended in Laemmli sample buffer,
boiled, and loaded onto an SDS-8% PAGE gel. Following
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FIG. 1. EBV viral transactivator domain structures predicted by
transcription and differential splicing in the EBV immediate-early
region. (A) Leftward transcripts derived from promoters pR and pZ
(41) with nucleotide coordinates according to the B95-8 strain of EBV
(1); shown are the polyadenylation site (P), TATA box (T), and
primers A, B, and C used in RNA-based PCR for identification of the
RAZ-specific splice versus the BRLF1-BZLF1 bicistronic transcripts.
(B) Functional domains of the R, Z, and putative RAZ proteins with
transactivation (TA), DNA-binding (DBD), and dimerization (DIM)
domains.
electrophoresis, the gel was transferred to polyvinylidene di-
fluoride membrane (Schleicher & Schuell) for 2 h at 140 mA
and then immunoblotted with EA-D monoclonal antibody
(Dupont no. 9240) and visualized by the chemiluminescence
method as specified by the manufacturer (Amersham).
RESULTS
The 0.8-kb transcript initiating at pR (Fig.1A) results from
alternate splicing of the 3.3-kb bicistronic transcript and yields
an mRNA with a portion of the amino terminus of BRLF1 and
the carboxy terminus of BZLF1. The predicted protein (RAZ)
would include the DNA-binding and coiled-coil dimerization
domains of BZLF1 (located in exons 3 and 4, respectively)
(Fig.1A), linked to the first 86 aa of BRLF1 to generate a
252-aa chimeric protein. The amino acids of R contain parts of
its DNA-binding and dimerization domains (Fig.1B); how-
ever, deletional analysis has demonstrated that these 86 aa
alone are insufficient for either of these functions (25, 42). The
first 80 aa of Z, which contain most of the Z transactivation
domain (16), are not present in RAZ.
RAZ-specific RNA appears during EBY reactivation. To
study the role of RAZ in the EBV cytolytic cycle, the induction
of RAZ mRNA was assessed by RNA-based PCR in the
Burkitt lymphoma cell line Akata. This line contains latent
EBV genomes that can be reactivated synchronously into the
1830 FURNARI ET AL.
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FIG. 2. Transcription of RAZ mRNA follows that of R/Z bicis-
tronic RNA. (A) Akata cells were induced with anti-human IgG, and
total RNA was harvested at various time points. First-strand cDNAs
were generated from 1 ,ug of total cellular RNA primed with oligo(dT).
Amplimer pairs indicated in Fig. lA, A:C and A:B, were used in
separate reactions for RAZ and R/Z-specific PCR amplification,
respectively. cDNA products were detected by oligonucleotide South-
ern blot hybridization. (B) Actin amplification was performed to
establish a subplateau level that could be used to estimate the initial
amount of first-strand cDNA used in each PCR. PCR amplification of
RAZ and the R/Z bicistronic cDNAs was performed multiple times
with various Akata cell inductions and always yielded similar expres-
sion kinetics.
virus-productive cycle by treatment with anti-human IgG (52).
PCR primers specific for either the 0.8-kb RAZ transcript or
the 4.0- and 3.3-kb BZLF1-BRLF1 bicistronic transcripts are
indicated in Fig. lA and are predicted to produce amplification
products of 553 and 768 bp, respectively. As shown in Fig. 2A,
amplification of cDNA specific for the 4.0- and 3.3-kb R/Z
bicistronic transcripts reveals that one or both are first induced
about 1 h postinduction, reach a plateau at 6 h, and have
decreased at 12 h. In contrast, cDNA specific for RAZ RNA
appears to be induced later and persists longer. The apparent
persistence of RAZ message at later times during disruption of
latency may suggest that its function involves inhibition of Z
activity or possibly activation of late promoters. Actin mRNA
amplification at a limited number of cycles indicated that
nearly equal amounts of RNA were employed at each time
point to generate the cDNAs (Fig. 2B). However, determina-
tion of the kinetics of induction of RAZ RNA requires direct
RNA measurements, which are in process.
RAZ inhibits transactivation of Z-responsive promoters.
Since RAZ could in theory dimerize with Z and alter its
DNA-binding and its transactivational capabilities, the RAZ
cDNA (cRAZ) was amplified and fully sequenced from a XgtlO
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N N a
cc ~~~~N
BMRF1 BHRF1 DNA-POL RSV
FIG. 3. Expression of RAZ protein suppresses transactivation of
early promoters by Z protein in transient assays. The promoter-CAT
construct pEA-BS-CAT (BMRF1), pBHRF1-CAT (BHRF1), pPOL-
CAT (DNA-POL), or pRSV-CAT (RSV) was cotransfected with a
control plasmid (pHDl013 [C]) or expression clone pCMV-RAZ
(RAZ), pEBV-ZIE (Z), or pEBV-R/Z (R/Z) or with both RAZ and Z
(RAZ & Z or RAZ & R/Z). The results are presented as average
percent acetylation (indicated on the ordinate). The bars above the
columns indicate the range of the percent acetylation. The experiments
with the BMRF1, BHRFI, and Rous sarcoma virus promoters were
performed in HeLa cells with 5 pLg of each promoter construct and 5
p.g of pEBV-ZIE and pCMV-RAZ. The experiments with the DNA-
POL promoter were performed in EBV-positive Raji cells with 10 jig
of pPOL-CAT, 2.5 jg of pCMV-R/Z, and 2.5 Fg of pCMV-RAZ. For
all assays, the amount of the DNA transfected was kept constant by
addition of pHD1013 or salmon sperm DNA in the transfection.
library made from the prototype EBV cell line, B95-8 (22).
cRAZ was cloned into the pHD1O13 expression vector driven
by the cytomegalovirus immediate-early promoter (13), desig-
nated pCMV-RAZ, and used for transient expression in
promoter-CAT assays. The effects of cRAZ expression on Z
transactivation were determined with several EBV early pro-
moters that respond to Z and contain ZREs (21, 26, 28, 38).
The BMRF1 and BHRF1 promoters linked to CAT were
cotransfected with a Z-expression vector, pEBV-ZIE (28), into
EBV-negative HeLa cells, resulting in activation of the two
promoters (Fig. 3). This transactivation was inhibited on
average 70% by the addition of pCMV-RAZ in the transfec-
tion. This result was duplicated in EBV-positive cells with the
BMRF1 promoter (data not shown). The EBV DNA poly-
merase promoter, which can be activated by an R-plus-Z
genomic expression clone (21), was also inefficiently activated
in the presence of RAZ (Fig. 3). Therefore, RAZ inhibits Z
transactivation of at least three early viral promoters, and
inhibition is observed in both EBV-positive and -negative cells.
The RAZ-dependent decrease in promoter activity is specific
for the promoters assayed since pCMV-RAZ does not de-
crease the activity of the Rous sarcoma virus long terminal
repeat (Rous sarcoma virus-CAT). A mutant of RAZ,
RAZADIM, which deletes the dimerization domain (Fig. 4),
did not affect activation of the BMRFI promoter by Z (Fig. 5).
The effect on promoter activity of a second mutant, RAZAR
(Fig. 4), is described subsequently.
The RAZ R domain negatively affects DNA-binding ability.
Since RAZ differs from Z only at the amino terminus (Fig.
I B), RAZ protein might still be expected to bind to a
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FIG. 4. Structure of RAZ mutants. The R domain (aa 1 to 86) and
dimerization domain (aa 207 to 235) of RAZ were deleted to create
RAZAR and RAZADIM, respectively.
cloning the RAZ cDNA into the pBS+ vector (Stratagene)
(pBScRAZ), and RNA transcribed from this vector was used
to program rabbit reticulocyte lysates. RAZ protein thus
produced did not bind to the ZRE-containing probe (Fig. 6,
lane 2) whereas Z protein produced from a similar vector
(pSP64Z, a gift from P. Farrell [51]) bound readily (lane 3).
Removal of the RAZ R domain (aa 1 to 86 from pBScRAZ)
results in a protein (RAZAR) that contains mainly the DNA-
binding and the dimerization domains of Z (Fig. 4). As shown
in Fig. 6 (lane 4), RAZAR gained the ability to bind to the
ZRE-containing probe. Thus, the R domain of RAZ is respon-
sible for inhibiting either protein dimerization or DNA-bind-
ing activity. The carboxy-terminal portion of the Z protein
(which is identical to the carboxy-terminal region of RAZ) is
sufficient for Z to bind to DNA (16).
Retic
Neg. RAZ Z RAZAR
1-*RAZAR:RAZAR
1 2 3 4
FIG. 6. The R domain of RAZ abolishes DNA binding. Shown are
results of an electrophoretic mobility-shift assay using 32P-end-labelled
ZRE-containing probe and rabbit reticulocyte lysate (lane 1) or lysates







FIG. 5. Effect of expression of mutated RAZ on an early promoter
activated by Z. Five micrograms of pEA-BS-CAT (BMRF1) was
cotransfected in HeLa cells with a control plasmid (pHD1O13),
expression plasmid pEBV-ZIE (Z), or Z plus pCMV-RAZ, pCMV-
RAZAR, or pCMV-RAZADIM. The results are shown as average fold
activation in duplicate assays. The bars above the columns indicate the
range.
The RAZ R domain does not impair protein dimerization.
To test the ability of RAZ protein to homodimerize and to
heterodimerize with Z, cRAZ was subcloned into pGEX2T for
overexpression in E. coli. 35S-labelled Z, RAZ, or RAZAR
proteins generated in vitro (Fig. 7, lanes 1 to 3) were incubated
with affinity-purified glutathione-S-transferase-RAZ (GST-
RAZ) fusion protein. A mutant of RAZ lacking the protein-
dimerization domain (aa 207 to 235), RAZADIM, served as a
negative control for dimerization (Fig. 4). GST complexes
resolved by SDS-PAGE showed that Z, RAZ, and RAZAR
could interact with GST-RAZ protein (Fig. 7, lanes 13 to 15).
In contrast, the mutant RAZADIM did not bind GST-RAZ
protein (lane 16). Neither glutathione-Sejharose beads alone
nor beads coated with GST bound the 5S-labelled proteins
(lanes 5 to 12). In a reciprocal experiment, GST-Z fusion
protein (a gift from D. Gutsch) and labelled RAZ proteins
(wild type and mutants) resulted in equivalent dimerization
(lanes 17 to 20). Thus, not only can RAZ homodimerize, it can
also heterodimerize with Z, suggesting that the effect of the R
sequence substituted in RAZ for the Z transactivation domain
is to inhibit DNA binding rather than dimerization.
RAZ sequesters Z into non-DNA-binding heterodimeric
complexes. Since RAZ could heterodimerize with Z, we next
addressed directly whether RAZ:Z or RAZ:RAZAR het-
erodimers result in a decrease in DNA-binding activity. A fixed
amount of BZLF1 transcript was cotranslated in vitro with
increasing amounts of either RAZAR or RAZ transcripts (Fig.
8, lanes 1 to 5), and cotranslation was followed by densitometry
to determine the molar ratio of the variable protein relative to
the constant protein. Analysis of binding to DNA of the
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FIG. 7. Dimerization potential of Z, RAZ, and RAZ mutants.
35S-labelled Z (lanes 1, 5, 9, 13, and 17), RAZ (lanes 2, 6, 10, 14, and
18), RAZAR (lanes 3, 7, 11, 15, and 19), and RAZADIM (lanes 4, 8,
12, 16, and 20) translated in rabbit reticulocyte lysates were assayed for
the ability to dimerize with bacterially expressed GST-RAZ (lanes 13
to 16) or GST-Z fusion proteins (lanes 17 to 20). Controls for
nonspecific interactions with 35S-labelled proteins are glutathione-
Sepharose beads alone (lanes 5 to 8) or glutathione-Sepharose beads
coated with affinity-purified GST (lanes 9 to 12). Molecular weight
markers (in thousands) are indicated on the right.
cotranslated products showed that increasing amounts of
RAZAR caused a decrease in binding of Z homodimers (Fig.
9A; compare lanes 2 and 3 with lane 1). With this decrease was
an increase in binding of Z:RAZAR heterodimers and
RAZAR homodimers to DNA (lanes 2 and 3). Next, the effect
of increasing amounts of RAZ was tested. As expected, Z
binding decreased, presumably because of RAZ:Z het-
erodimers that are unable to bind DNA (Fig. 9A; compare
lanes 4 and 5 with lane 1).
Since the sizes of RAZ and Z proteins are nearly identical,
it is difficult to know whether cotranslation of RAZ with Z
RNA caused a decrease in translation of the latter, which is
then reflected in an artifactual decrease in DNA binding by Z.
To answer this question, the truncated mutant, RAZAR, which
can bind to ZREs, was used in a similar cotranslation-DNA-
binding experiment. RAZAR RNA was kept as the constant
RNA in cotranslations with increasing amounts of Z or RAZ
RNA (Fig. 8, lanes 6 to 10). Increasing the amount of Z
protein caused a decrease in RAZAR homodimer binding
(Fig. 9B, lanes 6 to 8) and the appearance of RAZAR:Z
heterodimers (lanes 7 and 8) and Z homodimers (lane 8).
When an increasing amount of RAZ RNA was used, RAZAR
homodimer binding decreased (Fig. 9B; compare lanes 9 and
10 with lane 6) without the appearance of RAZ/AR:RAZ
heterodimers. Therefore, although such heterodimers form
(Fig. 7), they do not bind DNA. Quantitation of the decreases
in RAZAR and Z DNA binding as a result of heterodimeriza-
tion to RAZ is shown graphically in Fig. 9C. The decrease in
DNA binding by RAZAR:RAZ heterodimers is entirely due to
complex formation rather than to a decrease in translational
efficiency of RAZAR as determined by densitometric quanti-
tation of 35S-labelled RAZAR protein (Fig. 8, lanes 6 to 10).
Finally, in transient assays, RAZAR was able to interfere
with activation of the BMRF1 promoter by Z (Fig. 5, fourth
lane). This result is expected since Z:RAZAR heterodimers
(although nonfunctional) can bind to ZREs and compete with
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FIG. 8. Cotranslation of Z, RAZAR, and RAZ in vitro transcripts.
A fixed amount of Z transcript was translated in the presence of
[35S]methionine either alone (lane 1), with increasing amounts of
RAZAR transcript (lanes 2 and 3), or with increasing amounts of RAZ
transcript (lanes 4 and 5). A fixed amount of RAZAR transcript was
translated either alone (lane 6), with increasing amounts of Z tran-
script (lanes 7 and 8), or with increasing amounts of RAZ transcript
(lanes 9 and 10). Densitometry was performed on SDS-PAGE-
resolved translation products and normalized to methionine content.
Molar amounts of the proteins relative to the constant proteins are
indicated above each gel. Since RAZ and Z comigrate, the molar
amount of RAZ in lanes 4 and 5 was estimated by subtracting the
amount of Z protein that was translated in lane 1.
RAZ diminishes early replicative antigens induced by Z in
latently infected Raji cells. The biologic importance of Z was
first indicated by showing that transfection of Z het DNA into
Raji cells caused viral reactivation (9). We carried out a similar
experiment in Raji cells transfected with both RAZ and Z
expression clones. The index of viral reactivation was detection
of early antigen-diffuse (EA-D) complex by Western blots
(immunoblots). As shown in Fig. 10, viral reactivation induced
by Z could be reduced or prevented by expression of RAZ.
This result correlates well with the reversal produced by RAZ
of transactivation of the BMRF1 (EA-D) promoter by Z
shown in Fig. 3. Under these conditions, RAZ has a striking
biologic effect on latent infection which is the reciprocal of that
produced by Z.
Thus, in vitro RAZ acts as a transdominant repressor of Z
transactivation by forming heterodimers which are unable to
bind to ZREs. This is the first demonstration of such a
repressor mechanism among the herpesviruses and stands
unique among the alternately spliced transdominant repressors
whose usual inhibitory mechanism involves direct binding to
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FIG. 9. Analysis of DNA-binding potential of RAZ:Z and RAZ:
RAZAR heterodimers. For electrophoretic mobility shift assays, equal
amounts of unlabelled programmed reticulocyte lysate from Fig. 8
were reacted with the 32P-end-labelled ZRE-containing probe. (A) Z
protein alone (lane 1) and with increasing amounts of RAZAR protein
(lanes 2 and 3) or increasing amounts of RAZ protein (lanes 4 and 5).
(B) RAZAR protein alone (lane 6) and with increasing amounts of Z
protein (lanes 7 and 8) or increasing amounts of RAZ protein (lanes
9 and 10). The molar amounts of RAZAR, RAZ, or Z relative to the
constant proteins are indicated above the respective bars. (C) De-
creases in Z or RAZAR DNA binding as a result of heterodimeriza-
tion with RAZ, relative to the controls in panels A and B, were
measured by densitometry and are presented graphically. Lanes used
for each densitometry sample are indicated below each column and
refer to lanes shown in panels A and B. Triangles above the bars
indicate increasing molar amounts of RAZ. The exact amounts of
RAZ used are indicated above the corresponding lanes in panels A
and B.
DISCUSSION
In this paper, we demonstrate that a previously detected but
uncharacterized EBV gene product, RAZ, can modulate in
vitro the function of the single viral protein, Z, that initiates
viral reactivation. Moreover, RAZ has a biologic effect, as
shown by the ability of RAZ to curtail or prevent viral
reactivation induced by Z in latently infected cells. Although
viral proteins that augment the reactivation cascade are known
(7, 10, 26, 29), until now a virally encoded negative regulator of
Z function has not been proposed.
RAZ presents a new mechanism for transdominant repres-
sion of transcriptional activation. The predicted viral protein,
which has yet to be detected in vivo, is the result of alternate
splicing between the open reading frames encoding the imme-
diate-early transactivators, R and Z. We have shown that in
vitro RAZ acts as an inhibitor of Z activity by forming RAZ:Z
heterodimeric complexes which are unable to bind specific
DNA-response elements. This RAZ-dependent inhibition of
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FIG. 10. RAZ inhibits expression of early antigen (EA-D) in
induced Raji cells. Raji cells were transfected with a control plasmid
(pHD1013, lane 1) or expression clone pEBV-RIZ (lanes 2 to 5) and
increasing amounts of pCMV-RAZ (lanes 3 to 5). The cells were
harvested 24 h after transfection, and equal amounts of protein were
loaded onto an SDS-PAGE gel. The gel was transferred to a polyvi-
nylidene difluoride membrane and then blotted with 1:40 EA-D
monoclonal antibody (Dupont). Molecular weight markers (in thou-
sands) are indicated on the left.
DNA binding is the result of an 86-aa domain contributed to
the protein by R, replacing the Z transactivation domain.
Elements of such a transdominant mechanism have been
described for both viral and cellular systems (20). The bovine
papillomavirus E2 transactivator is differentially spliced to
yield two repressors, E2-TR and E8/E2 (8, 34, 35), both of
which share C-terminal DNA-binding and dimerization do-
mains with E2. Whereas E2-TR is a truncated form of E2,
E8/E2 contains the E8-coding sequence replacing the transac-
tivation domain of E2, a situation analogous to the generation
of RAZ transcripts. However, unlike RAZ the E8 open
reading frame does not inhibit E8/E2 homodimers or E8/
E2:E2 heterodimers from binding to DNA-recognition sites.
A similar strategy is used in cytolytic infections such as those
produced by adenovirus. The adenovirus ElA region contains
a single open reading frame that encodes both a positive and a
negative transcription regulatory factor. These two proteins
differ by 46 aa as a result of differential mRNA splicing (39).
However, unlike bovine papillomavirus E2 proteins, adenovi-
rus ElA does not bind DNA but mediates transcriptional
regulation through cellular transcription factors.
RAZ-like inhibition ofDNA binding has been demonstrated
with the cellular protein Id (inhibitor of DNA binding), which
associates with the basic helix-loop-helix proteins, MyoD, E12,
and E47, involved in muscle differentiation (2, 27). Unlike
RAZ, Id does not result from alternate splicing but is ex-
pressed from a unique gene; furthermore, Id exerts its poison-
ing effect because it lacks the basic domain region adjacent to
the helix-loop-helix domain that is essential for DNA binding.
A transcriptional regulatory protein such as RAZ which
combines inhibition ofDNA binding with alternate splicing has
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to RAZ is the recently described I-Rel protein which contains
a domain inhibitory to DNA binding within 121 amino-
terminal residues not found in other rel-related proteins (52).
I-Rel can heterodimerize with the p5O subunit of NF-KB to
inhibit DNA-binding activity. Deletion of the first 121 aa
generates a protein, I-Rel(A5'), that gains the ability to bind to
DNA as an I-Rel(A5'):p5O heterodimer, analogous to the
effect of the deletion of the R domain from RAZ. However,
like Id, I-Rel is expressed from a unique gene.
In transient assays, the viral protein RAZ can modulate
transcriptional activation by Z quite precisely. RAZ should be
able to regulate Z-induced EBV replication during disruption
of latency as shown in Fig. 10 and perhaps in primary infection
as well. A major regulatory role for RAZ will depend upon
demonstration that RAZ protein is produced in sufficient
amounts in infected cells to affect Z function. An important
aspect of the function of the Z transactivator is the synergistic
stimulation of transcription via multiple ZRE sites found in
numerous EBV promoters (4). Promoters containing the larg-
est number of ZRE sites are activated in in vitro transcription
assays at lower Z-protein concentrations. Thus, genes contain-
ing the greatest number of high-affinity ZREs would be
activated earlier, and genes with fewer sites would be activated
later as Z concentrations rise during the cytolytic cycle. The
results presented here have biologic implications for the EBV
reactivation mechanism in that transcriptionally active concen-
trations of Z can be altered by titration with RAZ into inactive
heterodimers. Thus, promoters which would be most sensitive
to Z concentration variations would contain one or two ZREs,
perhaps of low affinity.
Expression of RAZ RNA is governed by the same promoter
used for the bicistronic expression of the R and Z proteins
(41). The effect of the Z transactivator is first augmented by
the appearance of the R transactivator (10, 26) expressed from
the bicistronic mRNAs. An early RNA species having a size
similar to that of RAZ was detected by Biggin et al. (3). The
production of RAZ at a later time point after the early
promoters have been activated may then serve to limit poten-
tial toxicity of the Z protein and to promote the transition from
early to late gene expression and completion of the viral cycle.
Similar roles have been proposed for herpes simplex virus
ICP4 protein, which autoregulates its own expression by block-
ing transcription initiation (44, 50) and for the herpes simplex
virus virion host shutoff function, which downregulates imme-
diate-early and early gene expression by destabilizing mRNA
(33, 49). Another possibility being studied is that RAZ, since it
retains its DNA-binding domain, may bind to a late promoter.
Not understood are the cellular and viral functions that
modulate the kinetics and relative amounts of RAZ versus Z
RNAs generated by differential splicing. It is likely that the
mechanisms regulating splicing of the RAZ versus BRLF1-
BZLF1 bicistronic messages are dependent on cell type. In
certain cells, RAZ mRNA may be generated earlier or in
greater abundance than the bicistronic messages. In these
situations, it is possible that the ability of RAZ to inhibit
Z-induced activation of early EBV promoters may have the
effect of maintaining viral latency. The effect of Z can also be
modulated by cellular factors such as c-myb, a positive regula-
tor (30), and retinoic acid receptors, which are negative
regulators of Z (54). We have not yet confirmed which
EBV-infected cell types express RAZ protein because of the
current unavailability of high-affinity antibodies that distin-
guish between Z and RAZ. We are in the process of preparing
RAZ- and Z-specific antibodies that will allow us to determine
the biologic role of RAZ in EBV infection states.
A biologic role for RAZ is strongly suggested by results
shown in Fig. 10 in which increasing amounts of the RAZ
expression clone transfected in Raji cells dampened viral
reactivation induced by Z as assayed by reduction in amount of
EBV replicative antigen complex (EA-D) induced. This result
correlates with effects on the EA-D promoter shown in Fig. 2.
Similar experiments are being done in different cell lines, and
under different induction conditions, to test whether the
modulatory effect of RAZ may be related to tightness of the
latent state and ease of inducibility. Recently Miller (43) has
reviewed the original observations with induction by Z het
DNA, pointing out that some Z het preparations were ineffi-
cient in inducing viral reactivation for unknown reasons. It is
possible that these constructs also expressed RAZ. Thus, the
controls on viral reactivation are likely to engage a complex
interplay between programmed viral factors against a back-
ground of cellular factors that contribute to the process.
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